Protein Crystallography and Drug Discovery

The Practice of Medicinal Chemistry

Volumn , Issue , 2008, Pages 605-634

  Rondeau, Jean Michel ^a   Schreuder, Herman ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956304898     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374194-3.00030-5     Document Type: Chapter

References (191)

1. Shakespeare, W. Macbeth. Paris, 1977, Editions Aubier Montaigne.
2. Congreve M., Murray C.W., Blundell T.L. Structural biology and drug discovery. Drug Discov. Today, 2005, 10:895-907.
3. Scapin G. Structural biology and drug discovery. Curr. Pharm. Design, 2006, 12:2087-2097.
4. Tintelnot-Blomley M., Lewis R.A. A critical appraisal of structure-based drug design. IDrugs, 2006, 9:114-118.
5. Lombardino J.G., Lowe J.A. A guide to drug discovery: the role of the medicinal chemist in drug discovery - then and now. Nat. Rev. Drug Discov. 2004, 3:853-862.
6. Williams S.P., Kuyper L.F., Pearce K.H. Recent applications of protein crystallography and structure-guided drug design. Curr. Opin. Chem. Biol. 2005, 9:371-380.
7. Blundell T.L., Jhoti H., Abell C. High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discov. 2002, 1:45-54.
8. Hajduk P.J., Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 2006, 6:211-219.
9. Werten P.J.L., Remigy H.W., de Groot B.L., Fotiadis D., Philippsen A., Stahlberg H., Grubmuller H., Engel A. Progress in the analysis of membrane protein structure and function. FEBS Lett. 2002, 529:65-72.
10. Lundström K. Structural genomics for membrane proteins. Cell. Mol. Life Sci. 2006, 63:2597-2607.
11. Kendrew J.C., Bodo G., Dintzis H.M., Parrish R.G., Wyckoff H., Phillips D.C. 3-Dimensional model of the myoglobin molecule obtained by X-ray analysis. Nature, 1958, 181:662-666.
12. Perutz M.F., Rossmann M.G., Cullis A.F., Muirhead H., Will G., North A.C.T. Structure of haemoglobin-3-dimensional fourier synthesis at 5.5-A resolution, obtained by X-ray analysis. Nature, 1960, 185:416-422.
13. McPherson A. A brief history of protein crystal growth. J. Cryst. Growth, 1991, 110:1-10.
14. Franklin R.E., Gosling R.G. Evidence for 2-chain helix in crystalline structure of sodium deoxyribonucleate. Nature, 1953, 172:156-157.
15. Wilkins M.H.F., Seeds W.E., Stokes A.R., Wilson H.R. Helical structure of crystalline deoxypentose nucleic acid. Nature, 1953, 172:759-762.
16. Watson J.D., Crick F.H.C. Molecular structure of nucleic acids - a structure for deoxyribose nucleic acid. Nature, 1953, 171:737-738.
17. Perutz M. Protein Structure. New Approaches to Disease and Therapy 1992, W.H. Freeman and Company, New York.
18. Rossmann M.G., Arnold E., Erickson J.W., Frankenberger E.A., Griffith J.P., Hecht H.J., Johnson J.E., Kamer G., Luo M., Mosser A.G., Rueckert R.R., Sherry B., Vriend G. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 1985, 317:145-153.
19. Deisenhofer J., Epp O., Miki K., Huber R., Michel H. Structure of the protein subunits in the photosynthetic reaction center of Rhodopseudomonas viridis at 3Å resolution. Nature, 1985, 318:618-624.
20. Abrahams J.P., Leslie A.G., Lutter R., Walker J.E. Structure at 2.8 Å resolution of F1-ATPase from bovine heart mitochondria. Nature, 1994, 370:621-628.
21. Löwe J., Stock D., Jap B., Zwickl P., Baumeister W., Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 Å resolution. Science, 1995, 268:533-539.
22. Luger K., Mäder A.W., Richmond R.K., Sargent D.F., Richmond T.J. Crystal structure of the nucleosome core particle at 2.8Å. Nature, 1997, 389:251-260.
23. Brodersen D.E., Clemons W.M., Carter A.P., Morgan-Warren R.J., Wimberly B.T., Ramakrishnan V. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell, 2000, 103:1143-1154.
24. Ban N., Nissen P., Hansen J., Moore P.B., Steitz T.A. The complete atomic structure of the large ribosomal subunit at 2.4 A resolution. Science, 2000, 289:905-920.
25. Nissen P., Hansen J., Ban N., Moore P.B., Steitz T.A. The structural basis of ribosome activity in peptide bond synthesis. Science, 2000, 289:920-930.
26. Pioletti M., Schlunzen F., Harms J., Zarivach R., Gluhmann M., Avila H., Bashan A., Bartels H., Auerbach T., Jacobi C., Hartsch T., Yonath A., Franceschi F. Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3. EMBO J. 2001, 20:1829-1839.
27. Gnatt A.L., Cramer P., Fu J., Bushnell D.A., Kornberg R.D. Structural basis of transcription: an RNA polymerase II elongation complex at 3.3 Å resolution. Science, 2001, 292:1876-1882.
28. + conduction and selectivity. Science, 1998, 280:69-77.
29. Jiang Y., Lee A., Chen J., Cadene M., Chait B.T., MacKinnon R. Crystal structure and mechanism of a calcium-gated potassium channel. Nature, 2002, 417:515-522.
30. Sharff A., Jhoti H. High-throughput crystallography to enhance drug discovery. Curr. Opin. Chem. Biol. 2003, 7:340-345.
31. Kroemer M., Dreyer M.K., Wendt K.U. APRV - a program for automated data processing, refinement and visualization. Acta Cryst. D 2004, 60:1679-1682.
32. Mooij W.T.M., Hartshorn M.J., Tickle I.J., Sharff A.J., Verdonk M.L., Jhoti H. Automated protein-ligand crystallography for structure-based drug design. Chem. Med. Chem. 2006, 1:827-838.
33. Evrard G.X., Langer G.G., Perrakis A., Lamzin V.S. Assessment of automatic ligand building in ARP/Warp. Acta Cryst. D, 2007, 63:108-117.
34. Schmidt A., Lamzin V.S. Veni, vidi, vici - atomic resolution unraveling the mysteries of protein function. Curr. Opin. Struct. Biol. 2002, 12:698-703.
35. Petrova T., Podjarny A. Protein crystallography at subatomic resolution. Rep. Prog. Phys. 2004, 67:1565-1605.
36. Howard E.I., Sanishvili R., Cachau R.E., Mitschler A., Chevrier B., Barth P., Lamour V., Van Zandt M., Sibley E., Bon C., Moras D., Schneider T.R., Joachimiak A., Podjarny A. Ultrahigh resolution drug design I: details of interactions in human aldose reductase-inhibitor complex at 0.66 Å. Proteins Struct. Funct. Bioinf. 2004, 55:792-804.
37. El-Kabbani O., Darmanin C., Schneider T.R., Hazemann I., Ruiz F., Oka M., Joachimiak A., Schulze-Briese C., Tomizaki T., Mitschler A., Podjarny A. Ultrahigh resolution drug design II: atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors. Proteins Struct. Funct. Bioinf. 2004, 55:805-813.
38. Beddell C.R., Goodford P.J., Norrington F.E., Wilkinson S., Wootton R. Compounds designed to fit a site of known structure in human haemoglobin. Br. J. Pharmacol. 1976, 57:201-209.
39. Ondetti M.A., Cushman D.W. Design of specific inhibitors of angiotensin-converting enzyme - new class of orally active antihypertensive agents. Science 1977, 196:441-444.
40. Natesh R., Schwager S.L.U., Evans H.R., Sturrock E.D., Acharya K.R. Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry, 2004, 43:8718-8724.
41. Corradi H.R., Chitapi I., Sewell B.T., Georgiadis D., Dive V., Sturrock E.D., Acharya K.R. The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380. Biochemistry, 2007, 46:5473-5478.
42. Eriksson A.E., Jones T.A., Liljas A. Refined structure of human carbonic anhydrase II at 2.0 Å resolution. Proteins, 1988, 4:274-282.
43. Baldwin J., Ponticello G.S., Anderson P.S., Christy M.E., Murcko M.A., Randall W.C., Schwam H., Sugrue M.F., Springer J.P., Gautheron P., Grove J., Mallorga P., Viader M.-P., McKeever B.M., Navia M.A. Thienothiopyran-2-sulfonamides: novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma. J. Med. Chem. 1989, 32:2510-2513.
44. Pastorekova S., Parkkila S., Pastorek J., Supuran C.T. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J. Enzyme Inhib. Med. Chem. 2004, 19:199-229.
45. Briganti F., Mangani S., Orioli P., Scozzafava A., Vernaglione G., Supuran C.T. Carbonic anhydrase activators: X-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine. Biochemistry, 1997, 36:10384-10392.
46. Wade R.C. 'Flu' and structure-based drug design. Structure, 1997, 5:1139-1145.
47. Varghese J.N., Laver W.G., Colman P.M. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution. Nature, 1983, 303:35-40.
48. Colman P.M., Varghese J.N., Laver W.G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature, 1983, 303:41-44.
49. Goodford P.J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28:849-857.
50. von Itzstein M., Wu W.-Y., Kok G.B., Pegg M.S., Dyason J.C., Jin B., Van Phan T., Smythe M.L., White H.F., Oliver S.W., Colman P.M., Varghese J.N., Ryan D.M., Woods J.M., Bethell R.C., Hotham V.J., Cameron J.M., Penn C.R. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature, 1993, 363:418-423.
51. Kim C.U., Lew W., Williams M.A., Liu H., Zhang L., Swaminathan S., Bishofberger N., Chen M.S., Mendel D.B., Tai C.Y., Laver W.G., Stevens R.C. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 1997, 119:681-690.
52. Matter H., Schudok M. Recent advances in the design of matrix metalloprotease inhibitors. Curr. Opin. Drug Discov. Dev. 2004, 7:513-535.
53. Stout T.J., Foster P.G., Matthews D.J. High-throughput structural biology in drug discovery: protein kinases. Curr. Pharm. Design, 2004, 10:1069-1082.
54. Johnson S.L., Pellecchia M. Structure- and fragment-based approaches to protease inhibition. Curr. Top. Med. Chem. 2006, 6:317-329.
55. Knapp M., Bellamacina C., Murray J.M., Bussiere D.E. Targeting cancer: the challenges and successes of structure-based drug design against the human purinome. Curr. Top. Med. Chem. 2006, 6:1129-1159.
56. Thomas M.P., McInnes C. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle. IDrugs, 2006, 9:273-278.
57. Combs A.P. Structure-based drug design of new leads for phosphatase research. IDrugs, 2006, 10:112-115.
58. Wlodawer A. Rational approach to AIDS drug design through structural biology. Annu. Rev. Med. 2002, 53:595-614.
59. Hardy L.W., Malikayil A. The impact of structure-guided drug design on clinical agents. Curr. Drug Discov. 2003, (Dec):15-20.
60. Eder J., Hommel U., Cumin F., Martoglio B., Gerhartz B. Aspartic proteases in drug discovery. Curr. Pharm. Design, 2007, 13:271-285.
61. Ondetti M.A., Cushman D.W. Enzymes of the renin-angiotensin system and their inhibitors. Annu. Rev. Biochem. 1982, 51:283-308.
62. Blundell T.L., Cooper J., Foundling S.I., Jones D.M., Atrash B., Szelke M. On the rational design of renin inhibitors: X-ray studies of aspartic proteinases complexed with transition-state analogues. Biochemistry, 1987, 26:5585-5590.
63. Greenlee W.J. Renin inhibitors. Med. Res. Rev. 1990, 10:173-236.
64. Lunney E.A., Hamilton H.W., Hodges J.C., Kaltenbronn J.S., Repine J.T., Badasso M., Cooper J.B., Dealwis C., Wallace B.A., Lowther W.T., Dunn B.M., Humblet C. Analyses of ligand binding in five endothiapepsin crystal complexes and their use in the design and evaluation of novel renin inhibitors. J. Med. Chem. 1993, 36:3809-3820.
65. Sielecki A.R., Hayakawa K., Fujinaga M., Murphy M.E.P., Frazer M., Muir A.K., Carilli C.T., Lewicki J.A., Baxter J.D., James M.N.G. Structure of recombinant human renin, a target for cardio-vascular-active drugs, at 2.5 Å resolution. Science 1989, 243:1341-1351.
66. Rahuel J., Priestle J.P., Grütter M.G. The crystal structures of recombinant glycosylated human renin alone and in complex with a transition-state analog inhibitor. J. Struct. Biol. 1996, 107:227-236.
67. Navia M.A., Chaturvedi P.R. Design principles for orally bioavailable drugs. Drug Discov. Today, 1996, 1:179-189.
68. Rahuel J., Rasetti V., Maibaum J., Rüeger H., Göschke R., Cohen N.-C., Stutz S., Cumin F., Fuhrer W., Wood J.M., Grütter M.G. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human rennin. Chem. Biol. 2000, 7:493-504.
69. Wood J.M., Maibaum J., Rahuel J., Grütter M.G., Cohen N.-C., Rasetti V., Rüeger H., Göschke R., Stutz S., Fuhrer W., Schilling W., Rigollier P., Yamaguchi Y., Cumin F., Baum H.-P., Schnell C.R., Herold P., Mah R., Jensen C., O'Brien E., Stanton A., Bedigian M.P. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Comm. 2003, 308:698-705.
70. Göschke R., Stutz S., Rasetti V., Cohen N.-C., Rahuel J., Rigollier P., Baum H.-P., Forgiarini P., Schnell C.R., Wagner T., Gruetter M.G., Fuhrer W., Schilling W., Cumin F., Wood J.M., Maibaum J. Novel 2,7-dialky1 substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamide transition state peptidomimetics are potent and orally active inhibitors of human renin. J. Med. Chem. 2007, 50. 4818-4831.
71. Maibaum J., Stutz S., Göschke R., Rigollier P., Yamaguchi Y., Cumin F., Rahuel J., Baum H.-P., Cohen N.-C., Schnell C.R., Fuhrer W., Gruetter M.G., Schilling W., Wood J.M. Structural modification of the P2' position of 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent non-peptide human renin inhibitor active after once daily dosing in marmosets. J. Med. Chem. 2007, 50. 4832-4844.
72. Manning G., White D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science, 2002, 298:1912-1934.
73. Zimmermann J., Buchdunger E., Mett H., Meyer T., Lydon N.B. Potent and selective inhibitors of the Abl-kinase: phenylaminopyrimidine (PAP) derivatives. Bioorg. Med. Chem. Lett. 1997, 7:187-192.
74. Capdeville R., Buchdunger E., Zimmermann J., Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 2002, 1:493-502.
75. Scapin G. Structural biology in drug design: selective protein kinase inhibitors. Drug Discov. Today, 2002, 7:601-611.
76. Noble M.E.M., Endicott J.A., Johnson L.N. Protein kinase inhibitors: insights into drug design from structure. Science, 2004, 303:1800-1805.
77. Cowan-Jacob S.W. Structural biology of protein tyrosine kinases. Cell. Mol. Life Sci. 2006, 63:2608-2625.
78. Schindler T., Bommann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science, 2000, 289:1938-1942.
79. Nagar B., Bommann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T., Clarkson B., Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 2002, 62:4236-4243.
80. Manley P.W., Cowan-Jacob S.W., Buchdunger E., Fabbro D., Fendrich G., Furet P., Meyer T., Zimmermann J. Eur. J. Cancer, 2002, 38(Suppl. 5):S19-S27.
81. Cowan-Jacob S.W., Fendrich G., Floersheimer A., Furet P., Liebetanz J., Rummel G., Rheinberger P., Centeleghe M., Fabbro D., Manley P.W. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Cryst. D, 2007, 63:80-93.
82. Cowan-Jacob S.W., Guez V., Fendrich G., Griffin J.D., Fabbro D., Furet P., Liebetanz J., Mestan J., Manley P.W. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev. Med. Chem. 2004, 4:285-299.
83. Manley P.W., Breitenstein W., Bruggen J., Cowan-Jacob S.W., Furet P., Mestan J., Meyer T. Urea-derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases. Bioorg. Med. Chem. Lett. 2004, 14:5793-5797.
84. Manley P.W., Cowan-Jacob S.W., Fendrich G., Metan J. Molecular interactions between the highly selective pan-Bcr-Abl inhibitor, AMN107, and the tyrosine kinase domain of Abl. Blood, 2005, 106:940a.
85. Weisberg E., Manley P.W., Breitenstein W., Bruggen J., Cowan-Jacob S.W., Ray A., Huntly B., Fabbro D., Fendrich G., Hall-Meyers E., Kung A.L., Mestan J., Daley G.Q., Callahan L., Catley L., Cavazza C., Azam M., Neuberg D., Wright R.D., Gilliland D.G., Griffin J.D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 2005, 7:129-141.
86. Weisberg E., Manley P., Mestan J., Cowan-Jacob S., Ray A., Griffin J.D. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br. J. Cancer, 2006, 94:1765-1769.
87. Matthews B. Solvent content of protein crystals. J. Mol. Biol. 1968, 33:491-497.
88. Ducruix A., Giege R. Crystallization of Nucleic Acids and Proteins: A Practical Approach 1999, Oxford University Press, Oxford. 2nd Edition.
89. McPherson A. Crystallization of biological macromolecules 1999, Cold Spring Harbor Laboratory Press, New York.
90. Kundrot C.E. Which strategy for a protein crystallization project?. Cell. Mol. Life Sci. 2004, 61:525-536.
91. Pusey M.L., Liu Z.-J., Tempel W., Praissman J., Lin D., Wang B.-C., Gavira J.A., Ng J.D. Life in the fast lane for protein crystallization and X-ray crystallography. Prog. Biophys. Mol. Biol. 2005, 88:359-386.
92. Derewenda Z.S. The use of recombinant methods and molecular engineering in protein crystallization. Methods, 2004, 34:354-363.
93. Chang V.T., Crispin M., Aricescu A.R., Harvey D.J., Nettleship J.E., Fennelly J.A., Yu C., Boles K.S., Evans E.J., Stuart D.I., Dwek R.A., Jones E.Y., Owens R.J., Davis S.J. Glycoprotein structural genomics: solving the glycosylation problem. Structure, 2007, 15:267-273.
94. Wright P.E., Dyson H.J. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J. Mol. Biol. 1999, 293:321-331.
95. Wiener M.C. A pedestrian guide to membrane protein crystallization. Methods, 2004, 34:364-372.
96. Minor D.L. The neurobiologist's guide to structural biology: a primer on why macromolecular structure matters and how to evaluate structural data. Neuron, 2007, 54:511-533.
97. McPherson A., Cudney B. Searching for silver bullets: an alternative strategy for crystallizing macromolecules. J. Struct. Biol. 2006, 156:387-406.
98. Strauss A., Fendrich G., Horisberger M.A., Liebetanz J., Meyhack B., Schlaeppi J.-M., Schmitz R. Improved expression of kinases in Baculovirus-infected insect cells upon addition of specific kinase inhibitors to the culture helpful for structural studies. Protein Expr. Purif. 2007, 56, 167-176.
99. Hassell A.M., An G., Bledsoe R.K., Bynum J.M., CarterIII H.L., Deng S.-J.J., Gampe R.T., Grisard T.E., Madauss K.P., Nolte R.T., Rocque W.J., Wang L., Weaver K.L., Williams S.P., Wisely G.B., Xu R., Shewchuk L.M. Crystallization of protein-ligand complexes. Acta Cryst. D 2007, 63:72-79.
100. Lusty C. A gentle vapor-diffusion technique for cross-linking of protein crystals for cryocrystallography. J. Appl. Cryst. 1999, 32:106-112.
101. Garman E.F., Owen R.L. Cryocooling and radiation damage in macromolecular crystallography. Acta Cryst. D, 2006, 62:32-47.
102. Dauter Z., Dauter M., Dodson E. Jolly SAD. Acta Cryst. D, 2002, 58:494-506.
103. Ealick S.E. Advances in multiple wavelength anomalous diffraction crystallography. Curr. Opin. Chem. Biol. 2000, 4:495-499.
104. Dauter Z., Dauter M. Entering a new phase: using solvent halide ions in protein structure determination. Structure, 2001, 9:21-26.
105. Debreczeni J.É., Bunkóczi G., Ma Q., Blaser H., Sheldrick G.M. In-house measurement of the sulfur anomalous signal and its use for phasing. Acta Cryst. D, 2003, 59:688-696.
106. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The protein data bank. Nucleic Acids Res. 2000, 28:235-242.
107. Brünger A.T., Free R. Value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature, 1992, 355:472-475.
108. Jia Z., Vandonselaar M., Quail J.W., Delbaere L.T.J. Active-centre torsion-angle strain revealed in 1.6 Å-resolution structure of histidine-containing phosphocarrier protein. Nature, 1993, 361:94-97.
109. Chevrier B., Schalk C., D'Orchymont H., Rondeau J.-M., Moras D., Tarnus C. Crystal structure of Aeromonas proteolytica aminopeptidase: a prototypical member of the co-catalytic zinc enzyme family. Structure, 1994, 2:283-291.
110. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Cryst. 1993, 26:283-291.
111. Davis A.M., Teague S.J., Kleywegt G.J. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. Angew. Chem. Int. Ed. 2003, 42:2718-2736.
112. DePristo M.A., de Bakker P.I.W., Blundell T.L. Heterogeneity and inaccuracy in protein structures solved by X-ray crystallography. Structure, 2004, 12:831-838.
113. Teague S. Implications of protein flexibility for drug discovery. Nat. Rev. Drug Discov. 2003, 2:527-541.
114. Kleywegt G.J. Crystallographic refinement of ligand complexes. Acta Cryst. D 2007, 63:94-100.
115. Jahnke W., Widmer H. Protein NMR in biomedical research. Cell. Mol. Life Sci. 2004, 61:580-599.
116. Chung. C.-W. The use of biophysical methods increases success in obtaining liganded crystal structures. Acta Cryst. 2007, D63, 62-71.
117. Kleywegt G.J., Harris M.R., Zou J.Y., Taylor T.C., Wählby A., Jones T.A. The Uppsala electron-density server. Acta Cryst. D 2004, 60:2240-2249.
118. Overington J.P., Al-Lazikani B., Hopkins A.L. How many drug targets are there?. Nat. Rev. Drug Discov. 2006, 5:992-996.
119. Hopkins A.L., Groom C.R. The druggable genome. Nat. Rev. Drug Discov. 2002, 1:727-730.
120. Laskowski R.A., Watson J.D., Thornton J.M. Protein function prediction using local 3D templates. J. Mol. Biol. 2005, 351:614-626.
121. Binkowski T.A., Joachimiak A., Liang J. Protein surface analysis for function annotation in high-throughput structural genomics pipeline. Protein Sci. 2005, 14:2972-2981.
122. Morris R.J., Najmanovich R.J., Kahraman A., Thornton J.M. Real spherical harmonic expansion coefficients as 3D shape descriptors for protein binding pocket and ligand comparisons. Bioinformatics, 2005, 21:2347-2355.
123. Watson J.D., Sanderson S., Ezersky A., Savchenko A., Edwards A., Orengo C., Joachimiak A., Laskowski R., Thornton J.M. Towards fully automated structure-based function prediction in structural genomics: a case study. J. Mol. Biol. 2007, 367:1511-1522.
124. Gruber J., Zawaira A., Saunders R., Barrett C.P., Noble M.E.M. Computational analyses of the surface properties of protein-protein interfaces. Acta Cryst. D, 2007, 63:50-57.
125. Li H.L., Gao Z.T., Kang L., Zhang H.L., Yang K., Yu K.Q., Luo X.M., Zhu W.L., Chen K.X., Shen J.H., Wang X.C., Jiang H.L. TarFisDock: a web server for identifying drug targets with docking approach. Nucleic Acids Res 2006, 34:W219-W224.
126. Cai J.H., Han C., Hu T.C., Zhang J., Wu D.L., Wang F.D., Liu Y.Q., Ding J.P., Chen K.X., Yue J.M., Shen X., Jiang H.L. Peptide deformylase is a potential target for anti-Helicobacter pylori drugs: Reverse docking, enzymatic assay, and X-ray crystallography validation. Protein Sci. 2006, 15:2071-2081.
127. Rockey W.M., Elcock A.H. Rapid computational identification of the targets of protein kinase inhibitors. J. Med. Chem. 2005, 48:4138-4152.
128. Hermann J.C., Marti-Arbona R., Fedorov A.A., Fedorov E., Almo S.C., Shoichet B.K., Raushel F.M. Structure-based activity prediction for an enzyme of unknown function. Nature, 2007, 448. 775-779.
129. Knight Z.A., Shokat K.M. Chemical genetics: where genetics and pharmacology meet. Cell, 2007, 128:425-430.
130. Blair J.A., Rauh D., Kung C., Yun C.-H., Fan Q.-W., Rode H., Zhang C., Eck M.J., Weiss W.A., Shokat K.M. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat. Chem. Biol. 2007, 3:229-238.
131. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliver. Rev. 1997, 23:3-25.
132. Loging W., Harland L., Williams-Jones B. High-throughput electronic biology: mining information for drug discovery. Nat. Rev. Drug Discov. 2007, 6:220-230.
133. Blundell T.L., Sibanda B.L., Montalvao R.W., Brewerton S., Chelliah V., Worth C.L., Harmer N.J., Davies O., Burke D. Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery. Phil. Trans. R. Soc. B. 2006, 361:413-423.
134. Hardy J.A., Wells J.A. Searching for new allosteric sites in enzymes. Curr. Opin. Struct. Biol. 2004, 14:706-715.
135. Chène P. Drug targeting protein-protein interactions. ChemMedChem 2006, 1:400-411.
136. Varney M.D., Marzoni G.P., Palmer C.L., Deal J.G., Webber S., Welsh K.M., Bacquet R.J., Bartlett C.A., Morse C.A., Booth C.L.J., Herrmann S.M., Howland E.F., Ward R.W., White J. Crystal-structure-based design and synthesis of benz[cd]indole-containing inhibitors of thymidylate synthase. J. Med. Chem. 1992, 35:663-676.
137. Lam P.Y.S., Jadhav P.K., Eyermann C.J., Hodge C.N., Ru Y., Bacheler L.T., Meek J.L., Otto M.J., Rayner M.M., Wong Y.N., Chang C.-H., Weber P.C., Jackson D.A., Sharpe T.R., Erickson-Viitanen S. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science, 1994, 263:380-384.
138. Furet P., Meyer T., Strauss A., Raccuglia S., Rondeau J.-M. Structure-based design and protein X-ray analysis of a protein kinase inhibitor. Bioorg. Med. Chem. Lett. 2002, 12:221-224.
139. Warshakoon N.C., Wu S., Boyer A., Kawamoto R., Sheville J., Bhatt R.T., Renock S., Xu K., Pokross M., Zhou S., Walter R., Mekel M., Evdokimov A.G., East S. Design and synthesis of substituted pyridine derivatives as HIF-1α prolyl hydroxylase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16:5616-5620.
140. Herschhorn A., Lerman L., Weitman M., Gleenberg I.O., Nudelman A., Hizi A. De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug resistant variants. J. Med. Chem. 2007, 50:2370-2384.
141. Shoichet B.K. Virtual screening of chemical libraries. Nature, 2004, 432:862-865.
142. Klebe G. Virtual ligand screening: strategies, perspectives and limitations. Drug Discov. Today. 2006, 11:580-594.
143. Cavasotto C.N., Orry A.J.W. Ligand docking and structure-based virtual screening in drug discovery. Curr. Topics Med. Chem. 2007, 7:1006-1014.
144. Alvarez J.C. High-throughput docking as a source of novel drug leads. Curr. Opin. Chem. Biol. 2004, 8:365-370.
145. Jansen J.M., Martin E.J. Target-biased scoring approaches and expert systems in structure-based virtual screening. Curr. Opin. Chem. Biol. 2004, 8:359-364.
146. Zentgraf M., Steuber H., Koch C., La Motta C., Sartini S., Sotriffer C.A., Klebe G. How reliable are current docking approaches for structure-based drug design? Lessons from aldose reductase. Angew. Chem. Int. Ed. 2007, 46:3575-3578.
147. Paiva A.M., Vanderwall D.E., Blanchard J.S., Kozarich J.W., Williamson J.M., Kelly T.M. Inhibitors of dihydrodipicolinate reductase, a key enzyme in the diaminopimelate pathway of Mycobacterium tuberculosis. Biochim. Biophys. Acta. 2001, 1545:67-77.
148. Powers R.A., Morandi F., Shoichet B.K. Structure-based discovery of a novel, noncovalent inhibitor of AmpC β-lactamase. Structure, 2002, 10:1013-1023.
149. Soelaiman S., Wei B.Q., Bergson P., Lee Y.-S., Shen Y., Mrksich M., Shoichet B.K., Tang W.-J. Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J. Biol. Chem. 2003, 278:25990-25997.
150. Brenk R., Naerum L., Grädler U., Gerber H.-D., Garcia G.A., Reuter K., Stubbs M.T., Klebe G. Virtual screening for submicromolar leads of tRNA-guanine transglycosylase based on a new unexpected binding mode detected by crystal structure analysis. J. Med. Chem. 2003, 46:1133-1143.
151. Vangrevelinghe E., Zimmermann K., Schoepfer J., Portmann R., Fabbro D., Furet P. Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking. J. Med. Chem. 2003, 46:2656-2662.
152. Singh J., Chuaqui C.E., Boriack-Sjodin P.A., Lee W.-C., Pontz T., Corbley M.J., Cheung H.-K., Arduini R.M., Mead J.N., Newman M.N., Papadatos J.L., Bowes S., Josiah S., Ling L.E. Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI). Bioorg. Med. Chem. Lett. 2003, 13:4355-4359.
153. Kraemer O., Hazemann I., Podjarny A.D., Klebe G. Virtual screening for inhibitors of human aldose reductase. Proteins, 2004, 55:814-823.
154. Barril X., Brough P., Drysdale M., Hubbard R.E., Massey A., Surgenor A., Wright L. Structure-based discovery of a new class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15:5187-5191.
155. Hann M.M., Leach A.R., Harper G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 2001, 41:856-864.
156. Hopkins A.L., Groom C.R., Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today, 2004, 9:430-431.
157. Abad-Zapatero C. Ligand efficiency indices for effective drug discovery. Expert Opin. Drug Discov. 2007, 2:469-488.
158. Teague S.J., Davis A.M., Leeson P.D., Oprea T. The design of leadlike combinatorial libraries. Angew. Chem. Int. Ed. 1999, 38:3743-3748.
159. Congreve M., Carr R., Murray C., Jhoti H. A "rule of three" for fragment-based lead discovery?. Drug Discov. Today, 2003, 8:876-877.
160. Finkelstein A.V., Janin J. The price of lost freedom: entropy of bimolecular complex formation. Protein Eng. 1989, 3:1-3.
161. Murray C.W., Verdonk M.L. The consequences of translational and rotational entropy lost by small molecules on binding to proteins. J. Comput. Aided Mol. Des. 2002, 16:741-753.
162. Hajduk P.J., Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 2007, 6:211-219.
163. Rees D.C., Congreve M., Murray C.W., Carr R. Fragment-based lead discovery. Nat. Rev. Drug Discov. 2004, 3:660-672.
164. Fragment-based Approaches in Drug Discovery. Methods and Principles in Medicinal Chemistry (Jahnke, W.; Erlanson, D. A., Eds.), Vol. 34. Wiley-VCH, weinheim, Germany 2006.
165. Nienaber V., Wang J., Davidson D., Henkin J. Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite. J. Biol. Chem. 2000, 275:7239-7248.
166. Murray C.W., Callaghan O., Chessari G., Cleasby A., Congreve M., Frederickson M., Hartshorn M.J., McMenamin R., Patel S., Wallis N. Applications of fragment-based screening by X-ray crystallography to β-secretase. J. Med. Chem. 2007, 50:1116-1123.
167. Congreve M., Aharony D., Albert J., Callaghan O., Campbell J., Carr R.A.E., Chessari G., Cowan S., Edwards P.D., Frederickson M., McMenamin R., Murray C.W., Patel S., Wallis N. Applications of fragment-based screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of β-secretase. J. Med. Chem. 2007, 50:1124-1132.
168. Gill A.L., Frederickson M., Cleasby A., Woodhead S.J., Carr M.G., Woodhead A.J., Walker M.T., Congreve M.S., Devine L.A., Tisi D., O'Reilly M., Seavers L.C.A., Davis D.J., Curry J., Anthony R., Padova A., Murray C.W., Carr R.A.E., Jhoti H. Identification of novel p38α MAP kinase inhibitors using fragment-based lead generation. J. Med. Chem. 2005, 48:414-426.
169. Card G.L., Blasdel L., England B.P., Zhang C., Suzuki Y., Gillette S., Fong D., Ibrahim P.N., Artis D.R., Bollag G., Milburn M.V., Kim S.-H., Schlessinger J., Zhang K.Y.J. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat. Biotechnol. 2005, 23:201-207.
170. Holdgate G.A., Ward W.H.J. Measurements of binding thermodynamics in drug discovery. Drug Discov. Today, 2005, 10:1543-1550.
171. Brenk R., Klebe G. quot;Hot spot" analysis of protein-binding sites as a prerequisite for structure-based virtual screening and lead optimization. Meth. Prin. Med. Chem. 2006, 32:171-192.
172. Ciulli A., Williams G., Smith A.G., Blundell T.L., Abell C. Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods. J. Med. Chem. 2006, 49:4992-5000.
173. Gohlke H., Hendlich M., Klebe G. Predicting binding modes, binding affinities and "hot spots" for protein-ligand complexes using a knowledge-based scoring function. Perspect. Drug Discov. Des. 2000, 20:115-144.
174. Verdonk M.L., Cole J.C., Watson P., Gillet V., Willett P. Superstar: improved knowledge-based interaction fields for protein binding sites. J. Mol. Biol. 2001, 307:841-859.
175. Grzybowski B.A., Ishchenko A.V., Kim C.-Y., Topalov G., Chapman R., Christianson D.W., Whitesides G.M., Shakhnovich E.I. Combinatorial computational method gives new picomolar ligands for a known enzyme. Proc. Natl. Acad. Sci. USA. 2002, 99:1270-1273.
176. Perola E., Charifson P.S. Conformational analysis of drug-like molecules bound to proteins: an extensive study of ligand reorganization upon binding. J. Med. Chem. 2004, 47:2499-2510.
177. Kim E.E., Baker C.T., Dwyer M.D., Murcko M.A., Rao B.G., Tung R.D., Navia M.A. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 1995, 117:1181-1182.
178. Greer J., Erickson J.W., Baldwin J.J., Varney M.D. Application of the three-dimensional structures of protein target molecules in structure-based drug design. J. Med. Chem. 1994, 37:1035-1054.
179. MacPherson L.J., Bayburt E.K., Capparelli M.P., Bohacek R.S., Clarke F.H., Ghai R.D., Sakane Y., Berry C.J., Peppard J.V., Trapani A.J. Design and synthesis of an orally active macrocyclic neutral endopeptidase 24.11 inhibitor. J. Med. Chem. 1993, 36:3821-3828.
180. Kim S.-H., Pudzianowski A.T., Leavitt K.J., Barbosa J., McDonnell P.A., Metzler W.J., Rankin B.M., Liu R., Vaccaro W., Pitts W. Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg. Med. Chem. Lett. 2005, 15:1101-1106.
181. Ohtaka H., Velázquez-Campoy A., Xie D., Freire E. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug resistant mutants of the HIV-1 protease. Protein Science 2002, 11:1908-1916.
182. Mao C., Sudbeck E.A., Ventakatachalam T.K., Uckun F.M. Structure-based drug design of non-nucleoside inhibitors for wild-type and drug resistant HIV reverse transcriptase. Biochem. Pharmacol. 2000, 60:1251-1265.
183. Das K., Clark A.D., Lewi P.J., Heeres J., de Jonge M.R., Koymans L.M.H., Vinkers H.M., Daeyaert F., Ludovici D.W., Kukla M.J., De Corte B., Kavash R.W., Ho C.Y., Ye H., Lichtenstein M.A., Andries K., Pauwels R., de Béthune M.-P., Boyer P.L., Clark P., Hughes S.H., Janssen P.A.J., Arnold E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 2004, 47:2550-2560.
184. Velazquez-Campoy A., Todd M.J., Freire E. HIV-1 protease inhibitors: enthalpic versus entropic optimization of the binding affinity. Biochemistry, 2000, 39:2201-2207.
185. Brown F.J., Andisik D.W., Bernstein P.R., Bryant C.B., Ceccarelli C., Damewood J.R., Edwards P.D., Earley R.A., Feeney S., Green R.C., Gomes B., Kosmider B.J., Krell R.D., Shaw A., Steelman G.B., Thomas R.M., Vacek E.P., Veale C.A., Tuthill P.A., Warner P., Williams J.C., Wolanin D.J., Woolson S.A. Design of orally active, non-peptidic inhibitors of human leukocyte elastase. J. Med. Chem. 1994, 37:1259-1261.
186. Pierce A.C., Rao G., Bemis G.W. BREED: generating novel inhibitors through hybridization of known ligands. Application to CDK2, P38, and HIV protease. J. Med. Chem. 2004, 47:2768-2775.
187. Anderson, M., Beattie, J. F., Breault, G. A., Breed, J., Byth, K. F., Culshaw, J. D., Ellston, R. P. A., Green, S., Minshull, C. A., Norman, R. A.,. Pauptit, R. A., Stanway, J., Thomas, A. P., Jewsbury, P. J. Imidazo[1,2a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hydridisation. Bioorg. Med. Chem. Lett. 2003, 13, 3021-3026.
188. Terasaka T., Kinoshita T., Kuno M., Nakanishi I. A highly potent non-nucleoside adenosine deaminase inhibitor: efficient drug discovery by intentional lead hydridization. J. Am. Chem. Soc. 2004, 126:34-35.
189. Oefner C., Binggeli A., Breu V., Bur D., Clozel J.P., D'Arcy A., Dorn A., Fischli W., Gruninger F., Guller R., Hirth G., Marki H.P., Mathews S., Muller M., Ridley R.G., Stadler H., Vieira E., Wilhelm M., Winkler F.K., Wostl W. Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases?. Chem. Biol. 1999, 6:127-131.
190. Hartshorn M.J., Murray C.W., Cleasby A., Frederickson M., Tickle I.J., Jhoti H. Fragment-based lead discovery using X-ray crystallography. J. Med. Chem. 2005, 48:403-413.
191. Lesuisse, D., Lange, G., Deprez, P., Bénard, D., Schoot, B., Delettre, G., Marquette, J.-P., Broto, P., Jean-Baptiste, V., Bichet, P., Sarubbi, E., Mandine, E. SAR and X-ray. A new approach combining fragment-based screening and rational drug design: Application to the Discovery of Nanomolar Inhibitors of Src SH2. J. Med. Chem. 2002, 45, 2379-2387.